Global T-Cell Therapy Market By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III/Pivotal, FDA Approval); By Types (Tumor-infiltrating lymphocytes (TIL) therapy, Chimeric Antigen Receptor (CAR) T-cell therapy, Engineered T Cell Receptor (TCR) Therapy); By Indication (Blood Cancer, Lymphoma Cancer , Colorectal Cancer, Colon Cancer, Ovarian Cancer, Pancreatic Cancer, Liver Cancer, Lung Cancer, Multiple Myeloma , Others); By Application (Kids, Adults); By End Users (Healthcare Professionals , Cancer Treatment Centres , Research Centers, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Research and development of cancer diagnostics and treatment methods is gaining immense attention around the globe. Investment from both private and public entities for cancer research has increased considerably in the last decade. Cancer is the primary cause of death globally, as far as disease related deaths are concerned. Based on World Health Organization (WHO) statistics, cancer was responsible for the death of about 10 million individuals in 2020. In other words, cancer caused around 17% of the deaths in 2020. The leading cause of cancer based death is the use of tobacco, alcohol intake, obesity, amongst others. Scientists are increasingly working on developing efficient cancer treatment methods that can help in increasing the lifespan of individuals. The immune system is tasked with identifying the substance which are commonly found in the human body. When a foreign substance enters the body, the immune system attacks it to ensure that it doesn't cause harm in the future. T-cells, which comes under the white blood cell category, helps in the destruction of foreign substances to protect the human body. T-cell therapy in cancer application refers to the programming of T-cells for the identification and destruction of cancer cells in the body. It is also referred to as cell-based gene therapy, as it deals with the alteration of genes present in the T-cells to tackle the emerging cancer cells. T-cell therapy is being used for the treatment of lymphoma, leukaemia and myeloma, amongst others. The rise in demand for the faster treatment of cancer, coupled with the advancement in gene therapy that helps in the modification of T-cells is leading to the growth of the global T-Cell therapy market.
COVID-19 Impact:
The COVID-19 pandemic is expected to have a positive impact on the global T-Cell therapy market. Government bodies are increasingly trying to treat individuals who are affected by various cancers because they are at a higher risk of being drastically affected by the COVID-19 infection. The modification of T-cells for the creation of COVID-19 vaccines is being increasingly studied by researchers. Research based on the behaviour of T-cells in individuals who have taken Pfizer's vaccine is also being monitored in South Africa. The advanced monitoring performed by researchers for the treatment of cancer using T-cells during the pandemic is expected to lead to the growth of revenue in global T-Cell therapy market in the coming years.
In terms of revenue, the global T-Cell therapy market is growing at a CAGR of 12.45% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global T-Cell Therapy Market Revenue & Forecast, (US$ Million), 2018 – 2029
Application Outlook:
The use of T-cells in cancer treatment is being commonly used in adults, as the risk associated with this therapy is on the lower side in grown humans. Also, there is a greater occurrence of cancer cases in adults. Adults accounted for the highest market share in the global T-Cell therapy market in 2020 as far as the application of T-cell therapy in humans is concerned.
Region Outlook:
North America accounted for the highest share of revenue in the global T-Cell therapy market in terms of regional revenue. The U.S. and Canada has numerous companies that are working on developing T-cell treatment for individuals. Companies such as Amgen and Pfizer are spearheading T-cell therapy research, and these companies are also collaborating with researchers that are working on cancer treatment methods. Also, the region is seeing a growth in the number of cancer cases, especially amongst young adults, due to the change in lifestyle and food habits. Fast food consumption has seen a massive spike in the U.S., and cases of obesity is increasingly as a result of this. Furthermore, there is a growth in awareness about cancer diagnostics and advanced treatment methods such as T-cell therapy amongst individuals in the U.S. and Canada. These factors are responsible for North America emerging as the most prominent region in the global T-Cell therapy market.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global T-Cell therapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global T-Cell therapy market are:
- Amgen Inc.
- Autolus
- bluebird bio, Inc.
- Bristol-Myers Squibb Company
- Cartesian Therapeutics
- Celgene
- Fate Therapeutics
- Gilead Sciences, Inc.
- Juno Therapeutics
- JW Therapeutics
- Kite Pharma, Inc.
- Medigene AG
- Merck KGaA
- Miltenyi Biotech
- Novartis AG
- Pfizer Inc.
- Sorrento Therapeutics, Inc.
- TCR Therapeutics.
- Other Market Participants
Global T-Cell Therapy Market
By Clinical Trial Phase
- Preclinical
- Phase I
- Phase II
- Phase III/Pivotal
- FDA Approval
By Types
- Tumor-infiltrating lymphocytes (TIL) therapy
- Chimeric Antigen Receptor (CAR) T-cell therapy
- Engineered T Cell Receptor (TCR) Therapy
By Indication
- Blood Cancer
- Lymphoma Cancer
- Colorectal Cancer
- Colon Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Liver Cancer
- Lung Cancer
- Multiple Myeloma
- Others
By Application
- Kids
- Adults
By End Users
- Healthcare Professionals
- Cancer Treatment Centres
- Research Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2018 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of T-Cell Therapy Market
6.
Market
Synopsis: T-Cell Therapy Market
7.
T-Cell
Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in T-Cell Therapy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
T-Cell Therapy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on T-Cell Therapy Market
8.
Global
T-Cell Therapy Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global T-Cell Therapy Market Revenue (US$ Mn)
8.2. Global T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
8.2.1. Preclinical
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2018 -
2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2018 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2018 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2018 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2018 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2018 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Phase I
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2018 -
2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2018 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2018 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2018 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2018 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2018 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Phase II
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2018 -
2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2018 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2018 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2018 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2018 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2018 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Phase III/Pivotal
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2018 -
2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2018 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2018 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2018 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2018 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2018 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. FDA Approval
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2018 -
2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2018 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2018 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2018 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2018 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2018 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Clinical Trial Phase
9.
Global
T-Cell Therapy Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
9.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2018 -
2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2018 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2018 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2018 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2018 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2018 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2018 -
2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2018 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2018 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2018 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2018 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2018 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Engineered T Cell Receptor (TCR) Therapy
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2018 -
2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2018 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2018 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2018 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2018 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2018 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Types
10. Global T-Cell Therapy Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. Global T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
10.2.1. Blood Cancer
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2018 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2018 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2018 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2018 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2018 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2018 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Lymphoma Cancer
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2018 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2018 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2018 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2018 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2018 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2018 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Colorectal Cancer
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2018 -
2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2018 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2018 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2018 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2018 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2018 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.2.4. Colon Cancer
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2018 -
2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2018 - 2020
10.2.4.5.1.2. Market Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2018 - 2020
10.2.4.5.2.2. Market Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2018 - 2020
10.2.4.5.3.2. Market Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2018 - 2020
10.2.4.5.4.2. Market Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2018 - 2020
10.2.4.5.5.2. Market Forecast, 2021 - 2029
10.2.5. Ovarian Cancer
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2018 -
2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2018 - 2020
10.2.5.5.1.2. Market Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2018 - 2020
10.2.5.5.2.2. Market Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2018 - 2020
10.2.5.5.3.2. Market Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2018 - 2020
10.2.5.5.4.2. Market Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2018 - 2020
10.2.5.5.5.2. Market Forecast, 2021 - 2029
10.2.6. Pancreatic Cancer
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2018 -
2020
10.2.6.3. Market Forecast, 2021 - 2029
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2018 - 2020
10.2.6.5.1.2. Market Forecast, 2021 - 2029
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2018 - 2020
10.2.6.5.2.2. Market Forecast, 2021 - 2029
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2018 - 2020
10.2.6.5.3.2. Market Forecast, 2021 - 2029
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2018 - 2020
10.2.6.5.4.2. Market Forecast, 2021 - 2029
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2018 - 2020
10.2.6.5.5.2. Market Forecast, 2021 - 2029
10.2.7. Liver Cancer
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2018 -
2020
10.2.7.3. Market Forecast, 2021 - 2029
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2018 - 2020
10.2.7.5.1.2. Market Forecast, 2021 - 2029
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2018 - 2020
10.2.7.5.2.2. Market Forecast, 2021 - 2029
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2018 - 2020
10.2.7.5.3.2. Market Forecast, 2021 - 2029
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2018 - 2020
10.2.7.5.4.2. Market Forecast, 2021 - 2029
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2018 - 2020
10.2.7.5.5.2. Market Forecast, 2021 - 2029
10.2.8. Lung Cancer
10.2.8.1. Definition
10.2.8.2. Market Estimation and Penetration, 2018 -
2020
10.2.8.3. Market Forecast, 2021 - 2029
10.2.8.4. Compound Annual Growth Rate (CAGR)
10.2.8.5. Regional Bifurcation
10.2.8.5.1. North America
10.2.8.5.1.1. Market Estimation, 2018 - 2020
10.2.8.5.1.2. Market Forecast, 2021 - 2029
10.2.8.5.2. Europe
10.2.8.5.2.1. Market Estimation, 2018 - 2020
10.2.8.5.2.2. Market Forecast, 2021 - 2029
10.2.8.5.3. Asia Pacific
10.2.8.5.3.1. Market Estimation, 2018 - 2020
10.2.8.5.3.2. Market Forecast, 2021 - 2029
10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2018 - 2020
10.2.8.5.4.2. Market Forecast, 2021 - 2029
10.2.8.5.5. Latin America
10.2.8.5.5.1. Market Estimation, 2018 - 2020
10.2.8.5.5.2. Market Forecast, 2021 - 2029
10.2.9. Multiple Myeloma
10.2.9.1. Definition
10.2.9.2. Market Estimation and Penetration, 2018 -
2020
10.2.9.3. Market Forecast, 2021 - 2029
10.2.9.4. Compound Annual Growth Rate (CAGR)
10.2.9.5. Regional Bifurcation
10.2.9.5.1. North America
10.2.9.5.1.1. Market Estimation, 2018 - 2020
10.2.9.5.1.2. Market Forecast, 2021 - 2029
10.2.9.5.2. Europe
10.2.9.5.2.1. Market Estimation, 2018 - 2020
10.2.9.5.2.2. Market Forecast, 2021 - 2029
10.2.9.5.3. Asia Pacific
10.2.9.5.3.1. Market Estimation, 2018 - 2020
10.2.9.5.3.2. Market Forecast, 2021 - 2029
10.2.9.5.4. Middle East and Africa
10.2.9.5.4.1. Market Estimation, 2018 - 2020
10.2.9.5.4.2. Market Forecast, 2021 - 2029
10.2.9.5.5. Latin America
10.2.9.5.5.1. Market Estimation, 2018 - 2020
10.2.9.5.5.2. Market Forecast, 2021 - 2029
10.2.10. Others
10.2.10.1. Definition
10.2.10.2. Market Estimation and Penetration, 2018 -
2020
10.2.10.3. Market Forecast, 2021 - 2029
10.2.10.4. Compound Annual Growth Rate (CAGR)
10.2.10.5. Regional Bifurcation
10.2.10.5.1. North America
10.2.10.5.1.1. Market Estimation, 2018 - 2020
10.2.10.5.1.2. Market Forecast, 2021 - 2029
10.2.10.5.2. Europe
10.2.10.5.2.1. Market Estimation, 2018 - 2020
10.2.10.5.2.2. Market Forecast, 2021 - 2029
10.2.10.5.3. Asia Pacific
10.2.10.5.3.1. Market Estimation, 2018 - 2020
10.2.10.5.3.2. Market Forecast, 2021 - 2029
10.2.10.5.4. Middle East and Africa
10.2.10.5.4.1. Market Estimation, 2018 - 2020
10.2.10.5.4.2. Market Forecast, 2021 - 2029
10.2.10.5.5. Latin America
10.2.10.5.5.1. Market Estimation, 2018 - 2020
10.2.10.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Indication
11. Global T-Cell Therapy Market Analysis and
Forecasts, 2021 – 2029
11.1. Overview
11.2. Global T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
11.2.1. Kids
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2018 -
2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2018 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2018 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2018 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2018 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2018 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. Adults
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2018 -
2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2018 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2018 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2018 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2018 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2018 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for Channeling Investments
11.3.1. By Application
12. Global T-Cell Therapy Market Analysis and
Forecasts, 2021 – 2029
12.1. Overview
12.2. Global T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
12.2.1. Healthcare Professionals
12.2.1.1. Definition
12.2.1.2. Market Estimation and Penetration, 2018 -
2020
12.2.1.3. Market Forecast, 2021 - 2029
12.2.1.4. Compound Annual Growth Rate (CAGR)
12.2.1.5. Regional Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market Estimation, 2018 - 2020
12.2.1.5.1.2. Market Forecast, 2021 - 2029
12.2.1.5.2. Europe
12.2.1.5.2.1. Market Estimation, 2018 - 2020
12.2.1.5.2.2. Market Forecast, 2021 - 2029
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market Estimation, 2018 - 2020
12.2.1.5.3.2. Market Forecast, 2021 - 2029
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market Estimation, 2018 - 2020
12.2.1.5.4.2. Market Forecast, 2021 - 2029
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market Estimation, 2018 - 2020
12.2.1.5.5.2. Market Forecast, 2021 - 2029
12.2.2. Cancer
Treatment Centres
12.2.2.1. Definition
12.2.2.2. Market Estimation and Penetration, 2018 -
2020
12.2.2.3. Market Forecast, 2021 - 2029
12.2.2.4. Compound Annual Growth Rate (CAGR)
12.2.2.5. Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market Estimation, 2018 - 2020
12.2.2.5.1.2. Market Forecast, 2021 - 2029
12.2.2.5.2. Europe
12.2.2.5.2.1. Market Estimation, 2018 - 2020
12.2.2.5.2.2. Market Forecast, 2021 - 2029
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market Estimation, 2018 - 2020
12.2.2.5.3.2. Market Forecast, 2021 - 2029
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market Estimation, 2018 - 2020
12.2.2.5.4.2. Market Forecast, 2021 - 2029
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market Estimation, 2018 - 2020
12.2.2.5.5.2. Market Forecast, 2021 - 2029
12.2.3. Research Centers
12.2.3.1. Definition
12.2.3.2. Market Estimation and Penetration, 2018 -
2020
12.2.3.3. Market Forecast, 2021 - 2029
12.2.3.4. Compound Annual Growth Rate (CAGR)
12.2.3.5. Regional Bifurcation
12.2.3.5.1. North America
12.2.3.5.1.1. Market Estimation, 2018 - 2020
12.2.3.5.1.2. Market Forecast, 2021 - 2029
12.2.3.5.2. Europe
12.2.3.5.2.1. Market Estimation, 2018 - 2020
12.2.3.5.2.2. Market Forecast, 2021 - 2029
12.2.3.5.3. Asia Pacific
12.2.3.5.3.1. Market Estimation, 2018 - 2020
12.2.3.5.3.2. Market Forecast, 2021 - 2029
12.2.3.5.4. Middle East and Africa
12.2.3.5.4.1. Market Estimation, 2018 - 2020
12.2.3.5.4.2. Market Forecast, 2021 - 2029
12.2.3.5.5. Latin America
12.2.3.5.5.1. Market Estimation, 2018 - 2020
12.2.3.5.5.2. Market Forecast, 2021 - 2029
12.2.4. Others
12.2.4.1. Definition
12.2.4.2. Market Estimation and Penetration, 2018 -
2020
12.2.4.3. Market Forecast, 2021 - 2029
12.2.4.4. Compound Annual Growth Rate (CAGR)
12.2.4.5. Regional Bifurcation
12.2.4.5.1. North America
12.2.4.5.1.1. Market Estimation, 2018 - 2020
12.2.4.5.1.2. Market Forecast, 2021 - 2029
12.2.4.5.2. Europe
12.2.4.5.2.1. Market Estimation, 2018 - 2020
12.2.4.5.2.2. Market Forecast, 2021 - 2029
12.2.4.5.3. Asia Pacific
12.2.4.5.3.1. Market Estimation, 2018 - 2020
12.2.4.5.3.2. Market Forecast, 2021 - 2029
12.2.4.5.4. Middle East and Africa
12.2.4.5.4.1. Market Estimation, 2018 - 2020
12.2.4.5.4.2. Market Forecast, 2021 - 2029
12.2.4.5.5. Latin America
12.2.4.5.5.1. Market Estimation, 2018 - 2020
12.2.4.5.5.2. Market Forecast, 2021 - 2029
12.3. Key Segment for Channeling Investments
12.3.1. By End Users
13. North America T-Cell Therapy Market Analysis
and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. North America T-Cell Therapy Market Revenue
(US$ Mn)
13.2. North America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
13.2.1. Preclinical
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III/Pivotal
13.2.5. FDA Approval
13.3. North America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
13.3.1. Tumor-infiltrating lymphocytes (TIL) therapy
13.3.2. Chimeric Antigen Receptor (CAR) T-cell therapy
13.3.3. Engineered T Cell Receptor (TCR) Therapy
13.4. North America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
13.4.1. Blood Cancer
13.4.2. Lymphoma Cancer
13.4.3. Colorectal Cancer
13.4.4. Colon Cancer
13.4.5. Ovarian Cancer
13.4.6. Pancreatic Cancer
13.4.7. Liver Cancer
13.4.8. Lung Cancer
13.4.9. Multiple Myeloma
13.4.10. Others
13.5. North America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
13.5.1. Kids
13.5.2. Adults
13.6. North America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
13.6.1. Healthcare Professionals
13.6.2. Cancer
Treatment Centres
13.6.3. Research Centers
13.6.4. Others
13.7. North America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
13.7.1.1.1. Preclinical
13.7.1.1.2. Phase I
13.7.1.1.3. Phase II
13.7.1.1.4. Phase III/Pivotal
13.7.1.1.5. FDA Approval
13.7.1.2. U.S T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
13.7.1.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
13.7.1.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
13.7.1.2.3. Engineered T Cell Receptor (TCR) Therapy
13.7.1.3. U.S T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.1.3.1. Blood Cancer
13.7.1.3.2. Lymphoma Cancer
13.7.1.3.3. Colorectal Cancer
13.7.1.3.4. Colon Cancer
13.7.1.3.5. Ovarian Cancer
13.7.1.3.6. Pancreatic Cancer
13.7.1.3.7. Liver Cancer
13.7.1.3.8. Lung Cancer
13.7.1.3.9. Multiple Myeloma
13.7.1.3.10. Others
13.7.1.4. U.S T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
13.7.1.4.1. Kids
13.7.1.4.2. Adults
13.7.1.5. U.S T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
13.7.1.5.1. Healthcare Professionals
13.7.1.5.2. Cancer
Treatment Centres
13.7.1.5.3. Research Centers
13.7.1.5.4. Others
13.7.2. Canada
13.7.2.1. Canada T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
13.7.2.1.1. Preclinical
13.7.2.1.2. Phase I
13.7.2.1.3. Phase II
13.7.2.1.4. Phase III/Pivotal
13.7.2.1.5. FDA Approval
13.7.2.2. Canada T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
13.7.2.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
13.7.2.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
13.7.2.2.3. Engineered T Cell Receptor (TCR) Therapy
13.7.2.3. Canada T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.2.3.1. Blood Cancer
13.7.2.3.2. Lymphoma Cancer
13.7.2.3.3. Colorectal Cancer
13.7.2.3.4. Colon Cancer
13.7.2.3.5. Ovarian Cancer
13.7.2.3.6. Pancreatic Cancer
13.7.2.3.7. Liver Cancer
13.7.2.3.8. Lung Cancer
13.7.2.3.9. Multiple Myeloma
13.7.2.3.10. Others
13.7.2.4. Canada T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
13.7.2.4.1. Kids
13.7.2.4.2. Adults
13.7.2.5. Canada T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
13.7.2.5.1. Healthcare Professionals
13.7.2.5.2. Cancer
Treatment Centres
13.7.2.5.3. Research Centers
13.7.2.5.4. Others
13.7.3. Mexico
13.7.3.1. Mexico T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
13.7.3.1.1. Preclinical
13.7.3.1.2. Phase I
13.7.3.1.3. Phase II
13.7.3.1.4. Phase III/Pivotal
13.7.3.1.5. FDA Approval
13.7.3.2. Mexico T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
13.7.3.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
13.7.3.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
13.7.3.2.3. Engineered T Cell Receptor (TCR) Therapy
13.7.3.3. Mexico T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
13.7.3.3.1. Blood Cancer
13.7.3.3.2. Lymphoma Cancer
13.7.3.3.3. Colorectal Cancer
13.7.3.3.4. Colon Cancer
13.7.3.3.5. Ovarian Cancer
13.7.3.3.6. Pancreatic Cancer
13.7.3.3.7. Liver Cancer
13.7.3.3.8. Lung Cancer
13.7.3.3.9. Multiple Myeloma
13.7.3.3.10. Others
13.7.3.4. Mexico T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
13.7.3.4.1. Kids
13.7.3.4.2. Adults
13.7.3.5. Mexico T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
13.7.3.5.1. Healthcare Professionals
13.7.3.5.2. Cancer
Treatment Centres
13.7.3.5.3. Research Centers
13.7.3.5.4. Others
13.7.4. Rest of North America
13.7.4.1. Rest of North America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
13.7.4.1.1. Preclinical
13.7.4.1.2. Phase I
13.7.4.1.3. Phase II
13.7.4.1.4. Phase III/Pivotal
13.7.4.1.5. FDA Approval
13.7.4.2. Rest of North America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Types
13.7.4.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
13.7.4.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
13.7.4.2.3. Engineered T Cell Receptor (TCR) Therapy
13.7.4.3. Rest of North America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Indication
13.7.4.3.1. Blood Cancer
13.7.4.3.2. Lymphoma Cancer
13.7.4.3.3. Colorectal Cancer
13.7.4.3.4. Colon Cancer
13.7.4.3.5. Ovarian Cancer
13.7.4.3.6. Pancreatic Cancer
13.7.4.3.7. Liver Cancer
13.7.4.3.8. Lung Cancer
13.7.4.3.9. Multiple Myeloma
13.7.4.3.10. Others
13.7.4.4. Rest of North America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.4.4.1. Kids
13.7.4.4.2. Adults
13.7.4.5. Rest of North America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
13.7.4.5.1. Healthcare Professionals
13.7.4.5.2. Cancer
Treatment Centres
13.7.4.5.3. Research Centers
13.7.4.5.4. Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Clinical Trial Phase
13.8.3. By Types
13.8.4. By Indication
13.8.5. By Application
13.8.6. By End Users
14. Europe T-Cell Therapy Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Europe T-Cell Therapy Market Revenue (US$ Mn)
14.2. Europe T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.2.1. Preclinical
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III/Pivotal
14.2.5. FDA Approval
14.3. Europe T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
14.3.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.3.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.3.3. Engineered T Cell Receptor (TCR) Therapy
14.4. Europe T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
14.4.1. Blood Cancer
14.4.2. Lymphoma Cancer
14.4.3. Colorectal Cancer
14.4.4. Colon Cancer
14.4.5. Ovarian Cancer
14.4.6. Pancreatic Cancer
14.4.7. Liver Cancer
14.4.8. Lung Cancer
14.4.9. Multiple Myeloma
14.4.10. Others
14.5. Europe T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
14.5.1. Kids
14.5.2. Adults
14.6. Europe T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.1. Healthcare Professionals
14.6.2. Cancer
Treatment Centres
14.6.3. Research Centers
14.6.4. Others
14.7. Europe T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Country
14.7.1. France
14.7.1.1. France T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.7.1.1.1. Preclinical
14.7.1.1.2. Phase I
14.7.1.1.3. Phase II
14.7.1.1.4. Phase III/Pivotal
14.7.1.1.5. FDA Approval
14.7.1.2. France T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
14.7.1.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.1.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.1.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.1.3. France T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.1.3.1. Blood Cancer
14.7.1.3.2. Lymphoma Cancer
14.7.1.3.3. Colorectal Cancer
14.7.1.3.4. Colon Cancer
14.7.1.3.5. Ovarian Cancer
14.7.1.3.6. Pancreatic Cancer
14.7.1.3.7. Liver Cancer
14.7.1.3.8. Lung Cancer
14.7.1.3.9. Multiple Myeloma
14.7.1.3.10. Others
14.7.1.4. France T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.1.4.1. Kids
14.7.1.4.2. Adults
14.7.1.5. France T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
14.7.1.5.1. Healthcare Professionals
14.7.1.5.2. Cancer
Treatment Centres
14.7.1.5.3. Research Centers
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1. The UK T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.7.2.1.1. Preclinical
14.7.2.1.2. Phase I
14.7.2.1.3. Phase II
14.7.2.1.4. Phase III/Pivotal
14.7.2.1.5. FDA Approval
14.7.2.2. The UK T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
14.7.2.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.2.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.2.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.2.3. The UK T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.2.3.1. Blood Cancer
14.7.2.3.2. Lymphoma Cancer
14.7.2.3.3. Colorectal Cancer
14.7.2.3.4. Colon Cancer
14.7.2.3.5. Ovarian Cancer
14.7.2.3.6. Pancreatic Cancer
14.7.2.3.7. Liver Cancer
14.7.2.3.8. Lung Cancer
14.7.2.3.9. Multiple Myeloma
14.7.2.3.10. Others
14.7.2.4. The UK T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.2.4.1. Kids
14.7.2.4.2. Adults
14.7.2.5. The UK T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
14.7.2.5.1. Healthcare Professionals
14.7.2.5.2. Cancer
Treatment Centres
14.7.2.5.3. Research Centers
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1. Spain T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.7.3.1.1. Preclinical
14.7.3.1.2. Phase I
14.7.3.1.3. Phase II
14.7.3.1.4. Phase III/Pivotal
14.7.3.1.5. FDA Approval
14.7.3.2. Spain T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
14.7.3.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.3.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.3.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.3.3. Spain T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.3.3.1. Blood Cancer
14.7.3.3.2. Lymphoma Cancer
14.7.3.3.3. Colorectal Cancer
14.7.3.3.4. Colon Cancer
14.7.3.3.5. Ovarian Cancer
14.7.3.3.6. Pancreatic Cancer
14.7.3.3.7. Liver Cancer
14.7.3.3.8. Lung Cancer
14.7.3.3.9. Multiple Myeloma
14.7.3.3.10. Others
14.7.3.4. Spain T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.3.4.1. Kids
14.7.3.4.2. Adults
14.7.3.5. Spain T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
14.7.3.5.1. Healthcare Professionals
14.7.3.5.2. Cancer
Treatment Centres
14.7.3.5.3. Research Centers
14.7.3.5.4. Others
14.7.4. Germany
14.7.4.1. Germany T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
14.7.4.1.1. Preclinical
14.7.4.1.2. Phase I
14.7.4.1.3. Phase II
14.7.4.1.4. Phase III/Pivotal
14.7.4.1.5. FDA Approval
14.7.4.2. Germany T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Types
14.7.4.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.4.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.4.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.4.3. Germany T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Indication
14.7.4.3.1. Blood Cancer
14.7.4.3.2. Lymphoma Cancer
14.7.4.3.3. Colorectal Cancer
14.7.4.3.4. Colon Cancer
14.7.4.3.5. Ovarian Cancer
14.7.4.3.6. Pancreatic Cancer
14.7.4.3.7. Liver Cancer
14.7.4.3.8. Lung Cancer
14.7.4.3.9. Multiple Myeloma
14.7.4.3.10. Others
14.7.4.4. Germany T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Application
14.7.4.4.1. Kids
14.7.4.4.2. Adults
14.7.4.5. Germany T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By End Users
14.7.4.5.1. Healthcare Professionals
14.7.4.5.2. Cancer
Treatment Centres
14.7.4.5.3. Research Centers
14.7.4.5.4. Others
14.7.5. Italy
14.7.5.1. Italy T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
14.7.5.1.1. Preclinical
14.7.5.1.2. Phase I
14.7.5.1.3. Phase II
14.7.5.1.4. Phase III/Pivotal
14.7.5.1.5. FDA Approval
14.7.5.2. Italy T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
14.7.5.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.5.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.5.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.5.3. Italy T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
14.7.5.3.1. Blood Cancer
14.7.5.3.2. Lymphoma Cancer
14.7.5.3.3. Colorectal Cancer
14.7.5.3.4. Colon Cancer
14.7.5.3.5. Ovarian Cancer
14.7.5.3.6. Pancreatic Cancer
14.7.5.3.7. Liver Cancer
14.7.5.3.8. Lung Cancer
14.7.5.3.9. Multiple Myeloma
14.7.5.3.10. Others
14.7.5.4. Italy T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
14.7.5.4.1. Kids
14.7.5.4.2. Adults
14.7.5.5. Italy T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
14.7.5.5.1. Healthcare Professionals
14.7.5.5.2. Cancer
Treatment Centres
14.7.5.5.3. Research Centers
14.7.5.5.4. Others
14.7.6. Nordic Countries
14.7.6.1. Nordic Countries T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.6.1.1. Preclinical
14.7.6.1.2. Phase I
14.7.6.1.3. Phase II
14.7.6.1.4. Phase III/Pivotal
14.7.6.1.5. FDA Approval
14.7.6.2. Nordic Countries T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Types
14.7.6.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.6.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.6.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.6.3. Nordic Countries T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Indication
14.7.6.3.1. Blood Cancer
14.7.6.3.2. Lymphoma Cancer
14.7.6.3.3. Colorectal Cancer
14.7.6.3.4. Colon Cancer
14.7.6.3.5. Ovarian Cancer
14.7.6.3.6. Pancreatic Cancer
14.7.6.3.7. Liver Cancer
14.7.6.3.8. Lung Cancer
14.7.6.3.9. Multiple Myeloma
14.7.6.3.10. Others
14.7.6.4. Nordic Countries T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.6.4.1. Kids
14.7.6.4.2. Adults
14.7.6.5. Nordic Countries T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
14.7.6.5.1. Healthcare Professionals
14.7.6.5.2. Cancer
Treatment Centres
14.7.6.5.3. Research Centers
14.7.6.5.4. Others
14.7.6.6. Nordic Countries T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux Union
14.7.7.1. Benelux Union T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.7.1.1. Preclinical
14.7.7.1.2. Phase I
14.7.7.1.3. Phase II
14.7.7.1.4. Phase III/Pivotal
14.7.7.1.5. FDA Approval
14.7.7.2. Benelux Union T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Types
14.7.7.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.7.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.7.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.7.3. Benelux Union T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
14.7.7.3.1. Blood Cancer
14.7.7.3.2. Lymphoma Cancer
14.7.7.3.3. Colorectal Cancer
14.7.7.3.4. Colon Cancer
14.7.7.3.5. Ovarian Cancer
14.7.7.3.6. Pancreatic Cancer
14.7.7.3.7. Liver Cancer
14.7.7.3.8. Lung Cancer
14.7.7.3.9. Multiple Myeloma
14.7.7.3.10. Others
14.7.7.4. Benelux Union T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
14.7.7.4.1. Kids
14.7.7.4.2. Adults
14.7.7.5. Benelux Union T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
14.7.7.5.1. Healthcare Professionals
14.7.7.5.2. Cancer
Treatment Centres
14.7.7.5.3. Research Centers
14.7.7.5.4. Others
14.7.7.6. Benelux Union T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of Europe
14.7.8.1. Rest of Europe T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
14.7.8.1.1. Preclinical
14.7.8.1.2. Phase I
14.7.8.1.3. Phase II
14.7.8.1.4. Phase III/Pivotal
14.7.8.1.5. FDA Approval
14.7.8.2. Rest of Europe T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
14.7.8.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
14.7.8.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
14.7.8.2.3. Engineered T Cell Receptor (TCR) Therapy
14.7.8.3. Rest of Europe T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
14.7.8.3.1. Blood Cancer
14.7.8.3.2. Lymphoma Cancer
14.7.8.3.3. Colorectal Cancer
14.7.8.3.4. Colon Cancer
14.7.8.3.5. Ovarian Cancer
14.7.8.3.6. Pancreatic Cancer
14.7.8.3.7. Liver Cancer
14.7.8.3.8. Lung Cancer
14.7.8.3.9. Multiple Myeloma
14.7.8.3.10. Others
14.7.8.4. Rest of Europe T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
14.7.8.4.1. Kids
14.7.8.4.2. Adults
14.7.8.5. Rest of Europe T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
14.7.8.5.1. Healthcare Professionals
14.7.8.5.2. Cancer
Treatment Centres
14.7.8.5.3. Research Centers
14.7.8.5.4. Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Clinical Trial Phase
14.8.3. By Types
14.8.4. By Indication
14.8.5. By Application
14.8.6. By End Users
15. Asia Pacific T-Cell Therapy Market Analysis
and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn)
15.2. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
15.2.1. Preclinical
15.2.2. Phase I
15.2.3. Phase II
15.2.4. Phase III/Pivotal
15.2.5. FDA Approval
15.3. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
15.3.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.3.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.3.3. Engineered T Cell Receptor (TCR) Therapy
15.4. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
15.4.1. Blood Cancer
15.4.2. Lymphoma Cancer
15.4.3. Colorectal Cancer
15.4.4. Colon Cancer
15.4.5. Ovarian Cancer
15.4.6. Pancreatic Cancer
15.4.7. Liver Cancer
15.4.8. Lung Cancer
15.4.9. Multiple Myeloma
15.4.10. Others
15.5. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
15.5.1. Kids
15.5.2. Adults
15.6. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.1. Healthcare Professionals
15.6.2. Cancer
Treatment Centres
15.6.3. Research Centers
15.6.4. Others
15.7. Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
15.7.1.1.1. Preclinical
15.7.1.1.2. Phase I
15.7.1.1.3. Phase II
15.7.1.1.4. Phase III/Pivotal
15.7.1.1.5. FDA Approval
15.7.1.2. China T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
15.7.1.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.1.2.2. Chimeric
Antigen Receptor (CAR) T-cell therapy
15.7.1.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.1.3. China T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.1.3.1. Blood Cancer
15.7.1.3.2. Lymphoma Cancer
15.7.1.3.3. Colorectal Cancer
15.7.1.3.4. Colon Cancer
15.7.1.3.5. Ovarian Cancer
15.7.1.3.6. Pancreatic Cancer
15.7.1.3.7. Liver Cancer
15.7.1.3.8. Lung Cancer
15.7.1.3.9. Multiple Myeloma
15.7.1.3.10. Others
15.7.1.4. China T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
15.7.1.4.1. Kids
15.7.1.4.2. Adults
15.7.1.5. China T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
15.7.1.5.1. Healthcare Professionals
15.7.1.5.2. Cancer
Treatment Centres
15.7.1.5.3. Research Centers
15.7.1.5.4. Others
15.7.2. Japan
15.7.2.1. Japan T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
15.7.2.1.1. Preclinical
15.7.2.1.2. Phase I
15.7.2.1.3. Phase II
15.7.2.1.4. Phase III/Pivotal
15.7.2.1.5. FDA Approval
15.7.2.2. Japan T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
15.7.2.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.2.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.2.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.2.3. Japan T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.2.3.1. Blood Cancer
15.7.2.3.2. Lymphoma Cancer
15.7.2.3.3. Colorectal Cancer
15.7.2.3.4. Colon Cancer
15.7.2.3.5. Ovarian Cancer
15.7.2.3.6. Pancreatic Cancer
15.7.2.3.7. Liver Cancer
15.7.2.3.8. Lung Cancer
15.7.2.3.9. Multiple Myeloma
15.7.2.3.10. Others
15.7.2.4. Japan T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
15.7.2.4.1. Kids
15.7.2.4.2. Adults
15.7.2.5. Japan T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
15.7.2.5.1. Healthcare Professionals
15.7.2.5.2. Cancer
Treatment Centres
15.7.2.5.3. Research Centers
15.7.2.5.4. Others
15.7.3. India
15.7.3.1. India T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
15.7.3.1.1. Preclinical
15.7.3.1.2. Phase I
15.7.3.1.3. Phase II
15.7.3.1.4. Phase III/Pivotal
15.7.3.1.5. FDA Approval
15.7.3.2. India T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
15.7.3.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.3.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.3.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.3.3. India T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
15.7.3.3.1. Blood Cancer
15.7.3.3.2. Lymphoma Cancer
15.7.3.3.3. Colorectal Cancer
15.7.3.3.4. Colon Cancer
15.7.3.3.5. Ovarian Cancer
15.7.3.3.6. Pancreatic Cancer
15.7.3.3.7. Liver Cancer
15.7.3.3.8. Lung Cancer
15.7.3.3.9. Multiple Myeloma
15.7.3.3.10. Others
15.7.3.4. India T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
15.7.3.4.1. Kids
15.7.3.4.2. Adults
15.7.3.5. India T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
15.7.3.5.1. Healthcare Professionals
15.7.3.5.2. Cancer
Treatment Centres
15.7.3.5.3. Research Centers
15.7.3.5.4. Others
15.7.4. New Zealand
15.7.4.1. New Zealand T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.4.1.1. Preclinical
15.7.4.1.2. Phase I
15.7.4.1.3. Phase II
15.7.4.1.4. Phase III/Pivotal
15.7.4.1.5. FDA Approval
15.7.4.2. New Zealand T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
15.7.4.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.4.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.4.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.4.3. New Zealand T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
15.7.4.3.1. Blood Cancer
15.7.4.3.2. Lymphoma Cancer
15.7.4.3.3. Colorectal Cancer
15.7.4.3.4. Colon Cancer
15.7.4.3.5. Ovarian Cancer
15.7.4.3.6. Pancreatic Cancer
15.7.4.3.7. Liver Cancer
15.7.4.3.8. Lung Cancer
15.7.4.3.9. Multiple Myeloma
15.7.4.3.10. Others
15.7.4.4. New Zealand T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
15.7.4.4.1. Kids
15.7.4.4.2. Adults
15.7.4.5. New Zealand T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
15.7.4.5.1. Healthcare Professionals
15.7.4.5.2. Cancer
Treatment Centres
15.7.4.5.3. Research Centers
15.7.4.5.4. Others
15.7.5. Australia
15.7.5.1. Australia T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
15.7.5.1.1. Preclinical
15.7.5.1.2. Phase I
15.7.5.1.3. Phase II
15.7.5.1.4. Phase III/Pivotal
15.7.5.1.5. FDA Approval
15.7.5.2. Australia T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Types
15.7.5.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.5.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.5.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.5.3. Australia T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Indication
15.7.5.3.1. Blood Cancer
15.7.5.3.2. Lymphoma Cancer
15.7.5.3.3. Colorectal Cancer
15.7.5.3.4. Colon Cancer
15.7.5.3.5. Ovarian Cancer
15.7.5.3.6. Pancreatic Cancer
15.7.5.3.7. Liver Cancer
15.7.5.3.8. Lung Cancer
15.7.5.3.9. Multiple Myeloma
15.7.5.3.10. Others
15.7.5.4. Australia T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Application
15.7.5.4.1. Kids
15.7.5.4.2. Adults
15.7.5.5. Australia T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By End Users
15.7.5.5.1. Healthcare Professionals
15.7.5.5.2. Cancer
Treatment Centres
15.7.5.5.3. Research Centers
15.7.5.5.4. Others
15.7.6. South Korea
15.7.6.1. South Korea T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.6.1.1. Preclinical
15.7.6.1.2. Phase I
15.7.6.1.3. Phase II
15.7.6.1.4. Phase III/Pivotal
15.7.6.1.5. FDA Approval
15.7.6.2. South Korea T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
15.7.6.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.6.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.6.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.6.3. South Korea T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
15.7.6.3.1. Blood Cancer
15.7.6.3.2. Lymphoma Cancer
15.7.6.3.3. Colorectal Cancer
15.7.6.3.4. Colon Cancer
15.7.6.3.5. Ovarian Cancer
15.7.6.3.6. Pancreatic Cancer
15.7.6.3.7. Liver Cancer
15.7.6.3.8. Lung Cancer
15.7.6.3.9. Multiple Myeloma
15.7.6.3.10. Others
15.7.6.4. South Korea T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
15.7.6.4.1. Kids
15.7.6.4.2. Adults
15.7.6.5. South Korea T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
15.7.6.5.1. Healthcare Professionals
15.7.6.5.2. Cancer
Treatment Centres
15.7.6.5.3. Research Centers
15.7.6.5.4. Others
15.7.7. Southeast Asia
15.7.7.1. Southeast Asia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.7.1.1. Preclinical
15.7.7.1.2. Phase I
15.7.7.1.3. Phase II
15.7.7.1.4. Phase III/Pivotal
15.7.7.1.5. FDA Approval
15.7.7.2. Southeast Asia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
15.7.7.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.7.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.7.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.7.3. Southeast Asia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
15.7.7.3.1. Blood Cancer
15.7.7.3.2. Lymphoma Cancer
15.7.7.3.3. Colorectal Cancer
15.7.7.3.4. Colon Cancer
15.7.7.3.5. Ovarian Cancer
15.7.7.3.6. Pancreatic Cancer
15.7.7.3.7. Liver Cancer
15.7.7.3.8. Lung Cancer
15.7.7.3.9. Multiple Myeloma
15.7.7.3.10. Others
15.7.7.4. Southeast Asia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
15.7.7.4.1. Kids
15.7.7.4.2. Adults
15.7.7.5. Southeast Asia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
15.7.7.5.1. Healthcare Professionals
15.7.7.5.2. Cancer
Treatment Centres
15.7.7.5.3. Research Centers
15.7.7.5.4. Others
15.7.7.6. Southeast Asia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1. Rest of Asia Pacific T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
15.7.8.1.1. Preclinical
15.7.8.1.2. Phase I
15.7.8.1.3. Phase II
15.7.8.1.4. Phase III/Pivotal
15.7.8.1.5. FDA Approval
15.7.8.2. Rest of Asia Pacific T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Types
15.7.8.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
15.7.8.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
15.7.8.2.3. Engineered T Cell Receptor (TCR) Therapy
15.7.8.3. Rest of Asia Pacific T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
15.7.8.3.1. Blood Cancer
15.7.8.3.2. Lymphoma Cancer
15.7.8.3.3. Colorectal Cancer
15.7.8.3.4. Colon Cancer
15.7.8.3.5. Ovarian Cancer
15.7.8.3.6. Pancreatic Cancer
15.7.8.3.7. Liver Cancer
15.7.8.3.8. Lung Cancer
15.7.8.3.9. Multiple Myeloma
15.7.8.3.10. Others
15.7.8.4. Rest of Asia Pacific T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.8.4.1. Kids
15.7.8.4.2. Adults
15.7.8.5. Rest of Asia Pacific T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.8.5.1. Healthcare Professionals
15.7.8.5.2. Cancer
Treatment Centres
15.7.8.5.3. Research Centers
15.7.8.5.4. Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Clinical Trial Phase
15.8.3. By Types
15.8.4. By Indication
15.8.5. By Application
15.8.6. By End Users
16. Middle East and Africa T-Cell Therapy Market
Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn)
16.2. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.2.1. Preclinical
16.2.2. Phase I
16.2.3. Phase II
16.2.4. Phase III/Pivotal
16.2.5. FDA Approval
16.3. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Types
16.3.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.3.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.3.3. Engineered T Cell Receptor (TCR) Therapy
16.4. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Indication
16.4.1. Blood Cancer
16.4.2. Lymphoma Cancer
16.4.3. Colorectal Cancer
16.4.4. Colon Cancer
16.4.5. Ovarian Cancer
16.4.6. Pancreatic Cancer
16.4.7. Liver Cancer
16.4.8. Lung Cancer
16.4.9. Multiple Myeloma
16.4.10. Others
16.5. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
16.5.1. Kids
16.5.2. Adults
16.6. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
16.6.1. Healthcare Professionals
16.6.2. Cancer
Treatment Centres
16.6.3. Research Centers
16.6.4. Others
16.7. Middle East and Africa T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1. Saudi Arabia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.1.1.1. Preclinical
16.7.1.1.2. Phase I
16.7.1.1.3. Phase II
16.7.1.1.4. Phase III/Pivotal
16.7.1.1.5. FDA Approval
16.7.1.2. Saudi Arabia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
16.7.1.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.7.1.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.7.1.2.3. Engineered
T Cell Receptor (TCR) Therapy
16.7.1.3. Saudi Arabia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
16.7.1.3.1. Blood Cancer
16.7.1.3.2. Lymphoma Cancer
16.7.1.3.3. Colorectal Cancer
16.7.1.3.4. Colon Cancer
16.7.1.3.5. Ovarian Cancer
16.7.1.3.6. Pancreatic Cancer
16.7.1.3.7. Liver Cancer
16.7.1.3.8. Lung Cancer
16.7.1.3.9. Multiple Myeloma
16.7.1.3.10. Others
16.7.1.4. Saudi Arabia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
16.7.1.4.1. Kids
16.7.1.4.2. Adults
16.7.1.5. Saudi Arabia T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
16.7.1.5.1. Healthcare Professionals
16.7.1.5.2. Cancer
Treatment Centres
16.7.1.5.3. Research Centers
16.7.1.5.4. Others
16.7.2. UAE
16.7.2.1. UAE T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
16.7.2.1.1. Preclinical
16.7.2.1.2. Phase I
16.7.2.1.3. Phase II
16.7.2.1.4. Phase III/Pivotal
16.7.2.1.5. FDA Approval
16.7.2.2. UAE T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
16.7.2.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.7.2.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.7.2.2.3. Engineered T Cell Receptor (TCR) Therapy
16.7.2.3. UAE T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
16.7.2.3.1. Blood Cancer
16.7.2.3.2. Lymphoma Cancer
16.7.2.3.3. Colorectal Cancer
16.7.2.3.4. Colon Cancer
16.7.2.3.5. Ovarian Cancer
16.7.2.3.6. Pancreatic Cancer
16.7.2.3.7. Liver Cancer
16.7.2.3.8. Lung Cancer
16.7.2.3.9. Multiple Myeloma
16.7.2.3.10. Others
16.7.2.4. UAE T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
16.7.2.4.1. Kids
16.7.2.4.2. Adults
16.7.2.5. UAE T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
16.7.2.5.1. Healthcare Professionals
16.7.2.5.2. Cancer
Treatment Centres
16.7.2.5.3. Research Centers
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1. Egypt T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
16.7.3.1.1. Preclinical
16.7.3.1.2. Phase I
16.7.3.1.3. Phase II
16.7.3.1.4. Phase III/Pivotal
16.7.3.1.5. FDA Approval
16.7.3.2. Egypt T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
16.7.3.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.7.3.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.7.3.2.3. Engineered T Cell Receptor (TCR) Therapy
16.7.3.3. Egypt T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
16.7.3.3.1. Blood Cancer
16.7.3.3.2. Lymphoma Cancer
16.7.3.3.3. Colorectal Cancer
16.7.3.3.4. Colon Cancer
16.7.3.3.5. Ovarian Cancer
16.7.3.3.6. Pancreatic Cancer
16.7.3.3.7. Liver Cancer
16.7.3.3.8. Lung Cancer
16.7.3.3.9. Multiple Myeloma
16.7.3.3.10. Others
16.7.3.4. Egypt T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
16.7.3.4.1. Kids
16.7.3.4.2. Adults
16.7.3.5. Egypt T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
16.7.3.5.1. Healthcare Professionals
16.7.3.5.2. Cancer
Treatment Centres
16.7.3.5.3. Research Centers
16.7.3.5.4. Others
16.7.4. Kuwait
16.7.4.1. Kuwait T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
16.7.4.1.1. Preclinical
16.7.4.1.2. Phase I
16.7.4.1.3. Phase II
16.7.4.1.4. Phase III/Pivotal
16.7.4.1.5. FDA Approval
16.7.4.2. Kuwait T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
16.7.4.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.7.4.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.7.4.2.3. Engineered T Cell Receptor (TCR) Therapy
16.7.4.3. Kuwait T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
16.7.4.3.1. Blood Cancer
16.7.4.3.2. Lymphoma Cancer
16.7.4.3.3. Colorectal Cancer
16.7.4.3.4. Colon Cancer
16.7.4.3.5. Ovarian Cancer
16.7.4.3.6. Pancreatic Cancer
16.7.4.3.7. Liver Cancer
16.7.4.3.8. Lung Cancer
16.7.4.3.9. Multiple Myeloma
16.7.4.3.10. Others
16.7.4.4. Kuwait T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
16.7.4.4.1. Kids
16.7.4.4.2. Adults
16.7.4.5. Kuwait T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
16.7.4.5.1. Healthcare Professionals
16.7.4.5.2. Cancer
Treatment Centres
16.7.4.5.3. Research Centers
16.7.4.5.4. Others
16.7.5. South Africa
16.7.5.1. South Africa T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.5.1.1. Preclinical
16.7.5.1.2. Phase I
16.7.5.1.3. Phase II
16.7.5.1.4. Phase III/Pivotal
16.7.5.1.5. FDA Approval
16.7.5.2. South Africa T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
16.7.5.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.7.5.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.7.5.2.3. Engineered T Cell Receptor (TCR) Therapy
16.7.5.3. South Africa T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
16.7.5.3.1. Blood Cancer
16.7.5.3.2. Lymphoma Cancer
16.7.5.3.3. Colorectal Cancer
16.7.5.3.4. Colon Cancer
16.7.5.3.5. Ovarian Cancer
16.7.5.3.6. Pancreatic Cancer
16.7.5.3.7. Liver Cancer
16.7.5.3.8. Lung Cancer
16.7.5.3.9. Multiple Myeloma
16.7.5.3.10. Others
16.7.5.4. South Africa T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
16.7.5.4.1. Kids
16.7.5.4.2. Adults
16.7.5.5. South Africa T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
16.7.5.5.1. Healthcare Professionals
16.7.5.5.2. Cancer
Treatment Centres
16.7.5.5.3. Research Centers
16.7.5.5.4. Others
16.7.6. Rest of Middle East & Africa
16.7.6.1. Rest of Middle East & Africa T-Cell
Therapy Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
16.7.6.1.1. Preclinical
16.7.6.1.2. Phase I
16.7.6.1.3. Phase II
16.7.6.1.4. Phase III/Pivotal
16.7.6.1.5. FDA Approval
16.7.6.2. Rest of Middle East & Africa T-Cell
Therapy Market Revenue (US$ Mn) and Forecasts, By Types
16.7.6.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
16.7.6.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
16.7.6.2.3. Engineered T Cell Receptor (TCR) Therapy
16.7.6.3. Rest of Middle East & Africa T-Cell
Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
16.7.6.3.1. Blood Cancer
16.7.6.3.2. Lymphoma Cancer
16.7.6.3.3. Colorectal Cancer
16.7.6.3.4. Colon Cancer
16.7.6.3.5. Ovarian Cancer
16.7.6.3.6. Pancreatic Cancer
16.7.6.3.7. Liver Cancer
16.7.6.3.8. Lung Cancer
16.7.6.3.9. Multiple Myeloma
16.7.6.3.10. Others
16.7.6.4. Rest of Middle East & Africa T-Cell
Therapy Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.4.1. Kids
16.7.6.4.2. Adults
16.7.6.5. Rest of Middle East & Africa T-Cell
Therapy Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.6.5.1. Healthcare Professionals
16.7.6.5.2. Cancer
Treatment Centres
16.7.6.5.3. Research Centers
16.7.6.5.4. Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Clinical Trial Phase
16.8.3. By Types
16.8.4. By Indication
16.8.5. By Application
16.8.6. By End Users
17. Latin America T-Cell Therapy Market Analysis
and Forecasts, 2021 - 2029
17.1. Overview
17.1.1. Latin America T-Cell Therapy Market Revenue
(US$ Mn)
17.2. Latin America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Clinical Trial Phase
17.2.1. Preclinical
17.2.2. Phase I
17.2.3. Phase II
17.2.4. Phase III/Pivotal
17.2.5. FDA Approval
17.3. Latin America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Types
17.3.1. Tumor-infiltrating lymphocytes (TIL) therapy
17.3.2. Chimeric Antigen Receptor (CAR) T-cell therapy
17.3.3. Engineered T Cell Receptor (TCR) Therapy
17.4. Latin America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Indication
17.4.1. Blood Cancer
17.4.2. Lymphoma Cancer
17.4.3. Colorectal Cancer
17.4.4. Colon Cancer
17.4.5. Ovarian Cancer
17.4.6. Pancreatic Cancer
17.4.7. Liver Cancer
17.4.8. Lung Cancer
17.4.9. Multiple Myeloma
17.4.10. Others
17.5. Latin America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
17.5.1. Kids
17.5.2. Adults
17.6. Latin America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By End Users
17.6.1. Healthcare Professionals
17.6.2. Cancer
Treatment Centres
17.6.3. Research Centers
17.6.4. Others
17.7. Latin America T-Cell Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Clinical Trial Phase
17.7.1.1.1. Preclinical
17.7.1.1.2. Phase I
17.7.1.1.3. Phase II
17.7.1.1.4. Phase III/Pivotal
17.7.1.1.5. FDA Approval
17.7.1.2. Brazil T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Types
17.7.1.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
17.7.1.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
17.7.1.2.3. Engineered T Cell Receptor (TCR) Therapy
17.7.1.3. Brazil T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Indication
17.7.1.3.1. Blood Cancer
17.7.1.3.2. Lymphoma Cancer
17.7.1.3.3. Colorectal Cancer
17.7.1.3.4. Colon Cancer
17.7.1.3.5. Ovarian Cancer
17.7.1.3.6. Pancreatic Cancer
17.7.1.3.7. Liver Cancer
17.7.1.3.8. Lung Cancer
17.7.1.3.9. Multiple Myeloma
17.7.1.3.10. Others
17.7.1.4. Brazil T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By Application
17.7.1.4.1. Kids
17.7.1.4.2. Adults
17.7.1.5. Brazil T-Cell Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
17.7.1.5.1. Healthcare Professionals
17.7.1.5.2. Cancer
Treatment Centres
17.7.1.5.3. Research Centers
17.7.1.5.4. Others
17.7.2. Argentina
17.7.2.1. Argentina T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Clinical Trial Phase
17.7.2.1.1. Preclinical
17.7.2.1.2. Phase I
17.7.2.1.3. Phase II
17.7.2.1.4. Phase III/Pivotal
17.7.2.1.5. FDA Approval
17.7.2.2. Argentina T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Types
17.7.2.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
17.7.2.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
17.7.2.2.3. Engineered T Cell Receptor (TCR) Therapy
17.7.2.3. Argentina T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Indication
17.7.2.3.1. Blood Cancer
17.7.2.3.2. Lymphoma Cancer
17.7.2.3.3. Colorectal Cancer
17.7.2.3.4. Colon Cancer
17.7.2.3.5. Ovarian Cancer
17.7.2.3.6. Pancreatic Cancer
17.7.2.3.7. Liver Cancer
17.7.2.3.8. Lung Cancer
17.7.2.3.9. Multiple Myeloma
17.7.2.3.10. Others
17.7.2.4. Argentina T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By Application
17.7.2.4.1. Kids
17.7.2.4.2. Adults
17.7.2.5. Argentina T-Cell Therapy Market Revenue (US$
Mn) and Forecasts, By End Users
17.7.2.5.1. Healthcare Professionals
17.7.2.5.2. Cancer
Treatment Centres
17.7.2.5.3. Research Centers
17.7.2.5.4. Others
17.7.3. Rest of Latin America
17.7.3.1. Rest of Latin America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase
17.7.3.1.1. Preclinical
17.7.3.1.2. Phase I
17.7.3.1.3. Phase II
17.7.3.1.4. Phase III/Pivotal
17.7.3.1.5. FDA Approval
17.7.3.2. Rest of Latin America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Types
17.7.3.2.1. Tumor-infiltrating lymphocytes (TIL) therapy
17.7.3.2.2. Chimeric Antigen Receptor (CAR) T-cell therapy
17.7.3.2.3. Engineered T Cell Receptor (TCR) Therapy
17.7.3.3. Rest of Latin America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Indication
17.7.3.3.1. Blood Cancer
17.7.3.3.2. Lymphoma Cancer
17.7.3.3.3. Colorectal Cancer
17.7.3.3.4. Colon Cancer
17.7.3.3.5. Ovarian Cancer
17.7.3.3.6. Pancreatic Cancer
17.7.3.3.7. Liver Cancer
17.7.3.3.8. Lung Cancer
17.7.3.3.9. Multiple Myeloma
17.7.3.3.10. Others
17.7.3.4. Rest of Latin America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.3.4.1. Kids
17.7.3.4.2. Adults
17.7.3.5. Rest of Latin America T-Cell Therapy Market
Revenue (US$ Mn) and Forecasts, By End Users
17.7.3.5.1. Healthcare Professionals
17.7.3.5.2. Cancer
Treatment Centres
17.7.3.5.3. Research Centers
17.7.3.5.4. Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Clinical Trial Phase
17.8.3. By Types
17.8.4. By Indication
17.8.5. By Application
17.8.6. By End Users
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2020
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. Amgen Inc.
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Autolus
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. bluebird bio, Inc.
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. Bristol-Myers Squibb Company
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Cartesian Therapeutics
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Celgene
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. Fate Therapeutics
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. Gilead Sciences, Inc.
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Juno Therapeutics
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. JW Therapeutics
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. Kite Pharma, Inc.
19.11.1. Company Details
19.11.2. Company Overview
19.11.3. Product Offerings
19.11.4. Key Developments
19.11.5. Financial Analysis
19.11.6. SWOT Analysis
19.11.7. Business Strategies
19.12. Medigene AG
19.12.1. Company Details
19.12.2. Company Overview
19.12.3. Product Offerings
19.12.4. Key Developments
19.12.5. Financial Analysis
19.12.6. SWOT Analysis
19.12.7. Business Strategies
19.13. Merck KGaA
19.13.1. Company Details
19.13.2. Company Overview
19.13.3. Product Offerings
19.13.4. Key Developments
19.13.5. Financial Analysis
19.13.6. SWOT Analysis
19.13.7. Business Strategies
19.14. Miltenyi Biotech
19.14.1. Company Details
19.14.2. Company Overview
19.14.3. Product Offerings
19.14.4. Key Developments
19.14.5. Financial Analysis
19.14.6. SWOT Analysis
19.14.7. Business Strategies
19.15. Novartis AG
19.15.1. Company Details
19.15.2. Company Overview
19.15.3. Product Offerings
19.15.4. Key Developments
19.15.5. Financial Analysis
19.15.6. SWOT Analysis
19.15.7. Business Strategies
19.16. Pfizer Inc.
19.16.1. Company Details
19.16.2. Company Overview
19.16.3. Product Offerings
19.16.4. Key Developments
19.16.5. Financial Analysis
19.16.6. SWOT Analysis
19.16.7. Business Strategies
19.17. Sorrento Therapeutics, Inc.
19.17.1. Company Details
19.17.2. Company Overview
19.17.3. Product Offerings
19.17.4. Key Developments
19.17.5. Financial Analysis
19.17.6. SWOT Analysis
19.17.7. Business Strategies
19.18. TCR Therapeutics.
19.18.1. Company Details
19.18.2. Company Overview
19.18.3. Product Offerings
19.18.4. Key Developments
19.18.5. Financial Analysis
19.18.6. SWOT Analysis
19.18.7. Business Strategies
19.19. Other Market Participants
20. Key Findings
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.